The Food and Drug Administration aims to make a decision on any drug marketing application within 10 months -- six months, if the drug is given a priority review. Many drugmakers hear back on the exact day of the deadline, referred to as the PDUFA date.

Optimer Pharmaceuticals (Nasdaq: OPTR) won't. The PDUFA date for its antibiotic, Dificid, is Monday, which happens to be Memorial Day. Unless the FDA starts working holidays -- don't count on it -- the company will likely get a decision on Friday, or maybe not until Tuesday.

In the big picture, a few days won't make a bit of difference. While antibiotics from Johnson & Johnson (NYSE: JNJ), Theravance (Nasdaq: THRX), and others have all had trouble getting past regulators in recent years, I don't see Optimer having much difficulty. Given the generally positive FDA documents, followed by a unanimous recommendation by the advisory committee, an approval seems likely, whether the FDA works to clear its desk for the three-day weekend or saves it for next week.

What kind of label Dificid will get, on the other hand, is still a bit of a mystery. The committee of outside experts split six to six over whether the lack of recurrences of infections was clinically meaningful. Optimer and marketing partner Cubist Pharmaceuticals (Nasdaq: CBST) would like to have the recurrence data on the label, because it's the biggest draw to using Dificid over ViroPharma's (Nasdaq: VPHM) Vancocin.

Personally, I think the FDA should just put the data on the label and let individual physicians make up their mind whether it's important or not. But the agency tends to be a little high and mighty when it comes to thinking that it knows what's best for patients -- that is its job, I guess. Figuring out which way the agency will go is a little tough.

What's your call? Take our poll, then fill in your further thoughts in the comment box below.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.